m+Medelevator.RU
← Поиск публикаций
Journal of clinical medicine · 2026

Midtrimester Evaluation of Fetal Heart with Fetal Heart Quantification (FetalHQ) Related to Maternal Pathology.

СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Giannubilo Stefano Raffaele, Grelloni Camilla, Cecchi Alessandro, Carboni Elisa, Maruotti Giuseppe Maria, Mannolini Sara, Merone Alessia Maria, Terrone Maria, Ciavattini Andrea

Аннотация

Background: Echocardiography currently represents the gold standard for the anatomical and functional assessment of the fetal heart by experienced operators. FetalHQ (VolusonTM) provides a semi-automated speckle-tracking analysis of the fetal heart with promising results for the reliable assessment of cardiac remodeling, specifically of size, shape, and contractility. Methods: We conducted a retrospective study comparing 108 controls, 119 obesity (BMI ≥ 30), 69 pre-pregnancy diabetes mellitus (DM), 41 gestational diabetes mellitus (GDM), and 37 early fetal growth restriction (FGR) cases (19+0-22+6 weeks). FetalHQ was utilized during midtrimester echocardiographic exams to evaluate fetal myocardial thickness and left ventricular mass. Results: Myocardial thickness was increased in DM (median 0.21 [IQR 0.17-0.23] cm) vs. controls (0.17 [0.15-0.21] cm; p < 0.01) and reduced in FGR (0.13 [0.11-0.18] cm; p < 0.01). Left ventricular mass increased in obesity (0.98 [0.62-1.19] g) and DM (1.12 [0.94-1.17] g) vs. controls (0.73 [0.56-0.97] g; both p < 0.01). Conclusions: Fetal cardiac remodeling, especially myocardial thickness and left ventricular mass adaptations, is detectable in fetuses from high-risk pregnancies starting from the second trimester. Advanced speckle-tracking techniques, such as fetalHQ, provide valuable early risk stratification and may support the need for systematic fetal cardiac screening and monitoring during gestation in selected groups of patients.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты